Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesExpanding Access to Triptans: Assessment of Clinical Outcome
Headache: The Journal of Head and Face Pain, 10/12/09
Cady R et al. – Providing a greater quantity of 10 mg rizatriptan orally disintegrating tablet (ODT) did not reduce the number of migraine days compared with providing 9 tablets per month for this population with episodic migraine with a frequency of 3–8 migraines per month. Regardless of quantity provided, rizatriptan was generally well tolerated.
Related Articles
Topiramate in migraine progression
The Journal of Headache and Pain, 10/21/09
Relevance Score: 69%
CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine
Expert Review of Neurotherapeutics, 11/12/09
Relevance Score: 68%
Controversies in migraine
Nurse Prescribing, 10/09/09
Relevance Score: 68%
Ankle-Brachial Index, a Screening for Peripheral Obstructive Arterial Disease, and Migraine – A Controlled Study
Headache: The Journal of Head and Face Pain, 10/07/09
Relevance Score: 68%
New drugs for migraine
The Journal of Headache and Pain, 10/05/09
Relevance Score: 68%
Today in Pain Management...keeping you current
Receive free subspecialty "5-minute updates" via email
Neurolytic blocks: When, How, Why
Agri, 12/08/09
Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect
Headache: The Journal of Head and Face Pain, 12/08/09
Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review
Headache: The Journal of Head and Face Pain, 12/07/09
Sponsor
Article Search
Sponsor